InsidersTradesSigma
基于 2 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
Explore the complete record of transactions filed by Richman Eric I, 董事长兼首席执行官. Officer active across 2 companies, notably Gain Therapeutics, Inc.. Aggregated, 7 disclosures have been recorded. Breakdown: 5 buys · 0 sell. Total volume traded: €57k. History available since 16 August 2021. The latest transaction was filed on 1 July 2024 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 条申报中的 7 条
Eric I. Richman is a Director and Chief Executive Officer of Gain Therapeutics, Inc. and NeuBase Therapeutics, Inc. In these roles, he oversees the operations of the companies and is responsible for the overall strategy. Eric leverages his expertise to lead these companies towards growth and innovation initiatives.